A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
← catalyst calendarSponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (industry) · GPCR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
85actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-20 | actual | When the study began enrolling |
| Primary completion | 2026-01-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Chronic Weight Management
Interventions
- Drug: aleniglipron or placebo
- Drug: aleniglipron or placebo
- Drug: aleniglipron or placebo
- Drug: aleniglipron or placebo
Primary outcomes
what the primary-completion date above is the date OFTreatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
measured Baseline and week 44
Adverse events of special interest
measured Baseline and week 44
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis
measured Baseline and week 44
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration
measured Baseline and week 44
Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature
measured Baseline and week 44
Permalink · GPCR's whole pipeline · Catalyst calendar · Every registered study · What changed